Women in pregnancy or breastfeeding (pregnancy-beta-HCG-test will be performed in women of childbearing age), known severe renal impairment (estimated glomerular filtration rate < 30 ml/min/1.73 m2), or patients receiving continuous renal replacement therapy (hemodialysis or peritoneal dialysis), or previous renal transplant, known severe liver disease (AST or ALT 5X above the reference value), patients diagnosed with HIV infection or patient with any other immunodeficiencies, patients with the previous diagnosis of cancer, patients with the previous diagnosis of hereditary angioedema, patients with previous ischemic myocardial disease, patients with previous thromboembolic disease, if the assisting physician considers that the participation of the patient in the study is not appropriate, either because it is not of clinical interest or because of any condition that does not allow the protocol to be followed safely, the patient will be transferred to any other hospital before the 28 days of follow-up or before a disclosure (discharge from hospital), receipt of any experimental treatment for COVID-19 virus infection within 30 days prior to molecular screening.

Women in pregnancy or breastfeeding (pregnancy-beta-HCG-test will be performed in women of childbearing age), known severe renal impairment (estimated glomerular filtration rate < 30 ml/min/1.73 m2), or patients receiving continuous renal replacement therapy (hemodialysis or peritoneal dialysis), or previous renal transplant, known severe liver disease (AST or ALT 5X above the reference value), patients diagnosed with HIV infection or patient with any other immunodeficiencies, patients with the previous diagnosis of cancer, patients with the previous diagnosis of hereditary angioedema, patients with previous ischemic myocardial disease, patients with previous thromboembolic disease, if the assisting physician considers that the participation of the patient in the study is not appropriate, either because it is not of clinical interest or because of any condition that does not allow the protocol to be followed safely, the patient will be transferred to any other hospital before the 28 days of follow-up or before a disclosure (discharge from hospital), receipt of any experimental treatment for COVID-19 virus infection within 30 days prior to molecular screening.